Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
Favorable safety profile observed to date, with limited hematological toxicity
Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need
Regulatory News:
